top of page
Market Insight
What the Boston Scientific–Penumbra acquisition signals, and why it matters for Wellumio Boston Scientific’s announced ~$14.5 billion acquisition of Penumbra marks one of the most significant medtech transactions in recent years. While often framed as a return to neurovascular intervention, the deeper signal is more consequential: time-critical acute care has become strategic infrastructure. For companies building upstream of intervention, the implications are material. From
5 days ago3 min read
Wellumio and MEYTEC Sign MoU to Pioneer Next-Generation Stroke Imaging and Telemedicine Integration
WERNEUCHEN, GERMANY & MELBOURNE, AUSTRALIA MEYTEC, a leader in telemedicine and mobile emergency care technologies, and Wellumio, an...
May 20, 20252 min read
.png)
_edited.jpg)
Keep up to date with the latest industry thinking
Market Insight
What the Boston Scientific–Penumbra acquisition signals, and why it matters for Wellumio Boston Scientific’s announced ~$14.5 billion acquisition of Penumbra marks one of the most significant medtech transactions in recent years. While often framed as a return to neurovascular intervention, the deeper signal is more consequential: time-critical acute care has become strategic infrastructure. For companies building upstream of intervention, the implications are material. From
Market Insight
What the Boston Scientific–Penumbra acquisition signals, and why it matters for Wellumio Boston Scientific’s announced ~$14.5 billion acquisition of Penumbra marks one of the most significant medtech transactions in recent years. While often framed as a return to neurovascular intervention, the deeper signal is more consequential: time-critical acute care has become strategic infrastructure. For companies building upstream of intervention, the implications are material. From
Wellumio and MEYTEC Sign MoU to Pioneer Next-Generation Stroke Imaging and Telemedicine Integration
WERNEUCHEN, GERMANY & MELBOURNE, AUSTRALIA MEYTEC, a leader in telemedicine and mobile emergency care technologies, and Wellumio, an...
Check back soon
Once posts are published, you’ll see them here.
Market Insight
What the Boston Scientific–Penumbra acquisition signals, and why it matters for Wellumio Boston Scientific’s announced ~$14.5 billion acquisition of Penumbra marks one of the most significant medtech transactions in recent years. While often framed as a return to neurovascular intervention, the deeper signal is more consequential: time-critical acute care has become strategic infrastructure. For companies building upstream of intervention, the implications are material. From
Let's talk
If you can help towards our mission of reshaping the future of imaging, we'd like to hear from you.
We believe that improving access to MR technology is key to solving long-standing health delivery challenges.
bottom of page